Poster 9: THE FINAL ANALYSIS OF EXPAND: A PHASE 1B, OPEN-LABEL, DOSE-FINDING
STUDY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND LOW
PLATELET COUNT (50 × 109/L TO < 100 × 109/L) AT BASELINE
Paola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan,
Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Françoise Boyer-Perrard,
Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire
Harrison, Pantelia Roussou, Monika Wroclawska, Kevin Majidi, Peter A.W. te Boekhorst,
Heinz Gisslinger
Poster 10: MOMELOTINIB DOSE-INTENSITY IS MAINTAINED IN JAK INHIBITOR NAÏVE
AND PREVIOUSLY JAK INHIBITOR TREATED INTERMEDIATE/HIGH RISK
MYELOFIBROSIS PATIENTS
Vikas Gupta, Åsa Derolf, Miklós Egyed, Marek Hus, Ilya Kirgner, Ewa Lech-Maranda, Jiri
Mayer, Adam Mead, Donal McLornan, Zsolt Nagy, Stephen Oh, Uwe Platzbecker, Jacek
Treliński, David Ross, Srdan Verstovsek, Bianca Xicoy, Sung-Soo Yoon, Gregg Smith, Mark
Kowalski, Ruben Mesa
Poster 11: HOW WE MANAGE A PATIENT WITH CHRONIC MYELOID LEUKAEMIA WITH
T315I MUTATION IN A RESOURCE RESTRICTED COUNTRY
Maduwanthi Jayaweera, Senani Williams, M N Dilhani
Poster 12: MOMELOTINIB’S SPLEEN, SYMPTOM AND ANEMIA EFFICACY IS MAINTAINED
IN INTERMEDIATE/HIGH RISK MYELOFIBROSIS PATIENTS WITH
THROMBOCYTOPENIA
Jean-Jacques Kiladjian, Uwe Platzbecker, Jiri Mayer, Árpád Illés, Witold Prejzner, Tomasz
Wozny, Doroteya Todorieva, Alessandro M. Vannucchi, Ilya Kirgner, Zsolt Nagy,
Sebastian Grosicki, Åsa Derolf, Mihaela Cornelia Lazaroiu, Sung-Soo Yoon, Yeow Tee
Goh, Nikolas von Bubnoff, Srdan Verstovsek, Barbara Klencke, Rafe Donahue, Ruben
Mesa
Poster 13: CLINICAL CASE OF PATIENT WITH CML
Maya Legatos
Poster 14: POST–ESSENTIAL THROMBOCYTHEMIA AND POST–POLYCYTHEMIA VERA
MYELOFIBROSIS – DIFFERENCES FROM PRIMARY MYELOFIBROSIS
Bárbara Marques, Rita Gomes, Carolina Afonso, Sara Duarte, Adriana Roque, Margarida
Coucelo, José Pedro Carda, Emília Cortesão, Letícia Ribeiro
Poster 15: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL
STUDY OF CPI-0610 AND RUXOLITINIB VS. PLACEBO AND
RUXOLITINIB IN JAKI-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS
John Mascarenhas, Claire Harrison, Aaron Gerds, Katarina Luptakova, Jessica Christo,
Jing Wang, Gozde Colak, James Shao, Suresh Bobba, Patrick Trojer, Jeffrey Humphrey,
Srdan Verstovsek
Poster 16: GELATINOUS TRANSFORMATION EVOLVED INTO AML IN A PATIENT WITH
POST-ET MYELOFIBROSIS
Ilina Micheva, Stela Dimitrova